| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenstrual Syndrome | 48 | 2023 | 99 | 8.980 |
Why?
|
| Pregnancy Complications | 33 | 2025 | 378 | 7.140 |
Why?
|
| Substance-Related Disorders | 29 | 2022 | 734 | 6.410 |
Why?
|
| Depressive Disorder, Major | 20 | 2021 | 255 | 4.120 |
Why?
|
| Pregnancy | 70 | 2025 | 2338 | 4.040 |
Why?
|
| Antidepressive Agents | 23 | 2022 | 225 | 3.670 |
Why?
|
| Motivational Interviewing | 10 | 2020 | 43 | 3.430 |
Why?
|
| Depressive Disorder | 31 | 2017 | 284 | 3.090 |
Why?
|
| Anxiety Disorders | 20 | 2022 | 192 | 3.070 |
Why?
|
| Pregnancy Outcome | 12 | 2019 | 194 | 2.610 |
Why?
|
| Premature Birth | 13 | 2025 | 112 | 2.510 |
Why?
|
| Premenstrual Dysphoric Disorder | 4 | 2023 | 8 | 2.400 |
Why?
|
| Depression | 18 | 2021 | 894 | 2.400 |
Why?
|
| Female | 167 | 2025 | 32889 | 2.360 |
Why?
|
| Depression, Postpartum | 11 | 2019 | 129 | 2.230 |
Why?
|
| Adult | 115 | 2025 | 16830 | 1.960 |
Why?
|
| Mass Screening | 17 | 2022 | 690 | 1.920 |
Why?
|
| Prenatal Exposure Delayed Effects | 8 | 2022 | 158 | 1.840 |
Why?
|
| Referral and Consultation | 11 | 2020 | 422 | 1.830 |
Why?
|
| Humans | 178 | 2025 | 63467 | 1.770 |
Why?
|
| Psychiatric Status Rating Scales | 38 | 2021 | 390 | 1.740 |
Why?
|
| Panic Disorder | 14 | 2017 | 32 | 1.740 |
Why?
|
| Mood Disorders | 7 | 2016 | 72 | 1.710 |
Why?
|
| Crisis Intervention | 3 | 2022 | 27 | 1.580 |
Why?
|
| Opioid-Related Disorders | 9 | 2025 | 507 | 1.580 |
Why?
|
| Health Personnel | 7 | 2024 | 366 | 1.530 |
Why?
|
| Cigarette Smoking | 5 | 2019 | 57 | 1.480 |
Why?
|
| Stress Disorders, Post-Traumatic | 11 | 2024 | 397 | 1.420 |
Why?
|
| Postpartum Period | 9 | 2024 | 195 | 1.410 |
Why?
|
| Young Adult | 30 | 2025 | 4696 | 1.400 |
Why?
|
| Behavior, Addictive | 3 | 2022 | 73 | 1.370 |
Why?
|
| Surveys and Questionnaires | 16 | 2019 | 2679 | 1.330 |
Why?
|
| Sertraline | 12 | 2023 | 58 | 1.280 |
Why?
|
| Alcoholism | 7 | 2020 | 318 | 1.210 |
Why?
|
| Pregnancy, Unplanned | 5 | 2020 | 21 | 1.200 |
Why?
|
| Mental Disorders | 9 | 2025 | 791 | 1.190 |
Why?
|
| Alcohol Drinking | 3 | 2022 | 314 | 1.170 |
Why?
|
| Prospective Studies | 33 | 2021 | 3294 | 1.150 |
Why?
|
| Benzodiazepines | 4 | 2019 | 100 | 1.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2017 | 120 | 1.120 |
Why?
|
| Fluoxetine | 8 | 2022 | 44 | 1.110 |
Why?
|
| Anxiety | 7 | 2025 | 425 | 1.100 |
Why?
|
| Social Support | 6 | 2020 | 371 | 1.030 |
Why?
|
| Paroxetine | 6 | 2013 | 16 | 1.020 |
Why?
|
| Smoking | 6 | 2022 | 866 | 1.000 |
Why?
|
| Connecticut | 12 | 2017 | 90 | 0.980 |
Why?
|
| Menstrual Cycle | 8 | 2022 | 82 | 0.950 |
Why?
|
| Double-Blind Method | 19 | 2023 | 739 | 0.910 |
Why?
|
| Luteal Phase | 15 | 2023 | 28 | 0.910 |
Why?
|
| Women's Health | 7 | 2017 | 370 | 0.910 |
Why?
|
| Antidepressive Agents, Second-Generation | 6 | 2013 | 30 | 0.870 |
Why?
|
| Severity of Illness Index | 27 | 2016 | 1553 | 0.850 |
Why?
|
| Contraceptives, Oral, Hormonal | 3 | 2016 | 17 | 0.830 |
Why?
|
| Mothers | 3 | 2021 | 275 | 0.810 |
Why?
|
| Contraception | 2 | 2021 | 71 | 0.780 |
Why?
|
| Buprenorphine | 2 | 2025 | 192 | 0.770 |
Why?
|
| Intention | 2 | 2022 | 67 | 0.760 |
Why?
|
| Marijuana Use | 2 | 2019 | 21 | 0.750 |
Why?
|
| Reproductive Health Services | 2 | 2019 | 13 | 0.710 |
Why?
|
| Quality of Life | 13 | 2017 | 1228 | 0.700 |
Why?
|
| Adolescent | 26 | 2020 | 6253 | 0.700 |
Why?
|
| Progesterone | 2 | 2017 | 163 | 0.700 |
Why?
|
| Family Planning Services | 2 | 2022 | 21 | 0.690 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 724 | 0.680 |
Why?
|
| Life Change Events | 5 | 2016 | 66 | 0.670 |
Why?
|
| Treatment Outcome | 26 | 2023 | 5685 | 0.670 |
Why?
|
| Motivation | 3 | 2014 | 284 | 0.660 |
Why?
|
| Abortion, Spontaneous | 1 | 2019 | 31 | 0.630 |
Why?
|
| Recurrence | 12 | 2017 | 641 | 0.630 |
Why?
|
| Suicide | 2 | 2021 | 134 | 0.630 |
Why?
|
| Societies, Medical | 2 | 2019 | 379 | 0.630 |
Why?
|
| Interview, Psychological | 4 | 2019 | 78 | 0.630 |
Why?
|
| Androstenes | 3 | 2017 | 4 | 0.620 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 40 | 0.620 |
Why?
|
| Self Report | 2 | 2019 | 375 | 0.620 |
Why?
|
| Biological Psychiatry | 1 | 2019 | 2 | 0.610 |
Why?
|
| Infant, Newborn | 11 | 2022 | 1358 | 0.610 |
Why?
|
| Analgesia, Obstetrical | 1 | 2019 | 22 | 0.610 |
Why?
|
| Analgesics, Opioid | 3 | 2025 | 536 | 0.600 |
Why?
|
| Risk Factors | 20 | 2025 | 5356 | 0.590 |
Why?
|
| Comorbidity | 20 | 2015 | 1123 | 0.580 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2015 | 29 | 0.570 |
Why?
|
| Stress, Psychological | 3 | 2020 | 470 | 0.570 |
Why?
|
| Violence | 3 | 2016 | 170 | 0.560 |
Why?
|
| Middle Aged | 41 | 2025 | 17609 | 0.560 |
Why?
|
| Research Design | 5 | 2024 | 574 | 0.550 |
Why?
|
| Perinatal Care | 2 | 2025 | 64 | 0.550 |
Why?
|
| Bipolar Disorder | 5 | 2021 | 247 | 0.540 |
Why?
|
| Contraception Behavior | 1 | 2017 | 37 | 0.530 |
Why?
|
| Time Factors | 11 | 2017 | 3771 | 0.530 |
Why?
|
| Cost of Illness | 4 | 2017 | 162 | 0.530 |
Why?
|
| Health Status Indicators | 3 | 2007 | 93 | 0.530 |
Why?
|
| Secondary Prevention | 1 | 2017 | 164 | 0.510 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 206 | 0.510 |
Why?
|
| Biomedical Research | 4 | 2020 | 268 | 0.500 |
Why?
|
| Odds Ratio | 7 | 2016 | 768 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 771 | 0.490 |
Why?
|
| Crime Victims | 1 | 2016 | 35 | 0.480 |
Why?
|
| Body Weight | 2 | 2016 | 379 | 0.480 |
Why?
|
| Logistic Models | 8 | 2016 | 1277 | 0.480 |
Why?
|
| Phobic Disorders | 6 | 2005 | 15 | 0.480 |
Why?
|
| Infant, Premature | 2 | 2015 | 184 | 0.480 |
Why?
|
| Prenatal Care | 5 | 2022 | 170 | 0.470 |
Why?
|
| Contraceptives, Oral | 2 | 2005 | 23 | 0.470 |
Why?
|
| Inpatients | 3 | 2020 | 304 | 0.460 |
Why?
|
| Smoking Cessation | 2 | 2017 | 550 | 0.450 |
Why?
|
| Estrogens | 4 | 2005 | 116 | 0.450 |
Why?
|
| Research Personnel | 3 | 2020 | 94 | 0.440 |
Why?
|
| Ethinyl Estradiol | 3 | 2017 | 9 | 0.440 |
Why?
|
| Parenting | 2 | 2012 | 72 | 0.430 |
Why?
|
| Breast Feeding | 3 | 2019 | 151 | 0.420 |
Why?
|
| Counseling | 3 | 2016 | 362 | 0.420 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 168 | 0.420 |
Why?
|
| Massachusetts | 8 | 2017 | 2075 | 0.410 |
Why?
|
| Follow-Up Studies | 14 | 2012 | 2462 | 0.410 |
Why?
|
| Obstetrics | 3 | 2024 | 85 | 0.410 |
Why?
|
| United States | 13 | 2025 | 7842 | 0.400 |
Why?
|
| Prevalence | 9 | 2022 | 1380 | 0.400 |
Why?
|
| Gestational Age | 6 | 2017 | 189 | 0.400 |
Why?
|
| Pregnancy Trimesters | 2 | 2011 | 10 | 0.400 |
Why?
|
| Infant Behavior | 1 | 2012 | 4 | 0.390 |
Why?
|
| Cohort Studies | 10 | 2025 | 2569 | 0.390 |
Why?
|
| Anti-Anxiety Agents | 3 | 2004 | 32 | 0.380 |
Why?
|
| Hazardous Substances | 1 | 2012 | 15 | 0.380 |
Why?
|
| Emergency Service, Hospital | 5 | 2025 | 1101 | 0.380 |
Why?
|
| Social Control, Formal | 1 | 2012 | 20 | 0.370 |
Why?
|
| Pain | 1 | 2015 | 406 | 0.370 |
Why?
|
| Maternal Health Services | 2 | 2011 | 66 | 0.370 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2017 | 87 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 105 | 0.360 |
Why?
|
| Electronics | 2 | 2022 | 35 | 0.350 |
Why?
|
| Dietary Supplements | 1 | 2013 | 234 | 0.350 |
Why?
|
| Interviews as Topic | 5 | 2024 | 514 | 0.340 |
Why?
|
| 1-Naphthylamine | 5 | 1997 | 8 | 0.340 |
Why?
|
| Child of Impaired Parents | 2 | 2007 | 23 | 0.330 |
Why?
|
| Mother-Child Relations | 1 | 2010 | 46 | 0.330 |
Why?
|
| Reproductive Health | 2 | 2020 | 25 | 0.330 |
Why?
|
| Psychology | 2 | 2008 | 45 | 0.330 |
Why?
|
| Calcium | 1 | 2013 | 575 | 0.330 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 373 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 5 | 2020 | 311 | 0.320 |
Why?
|
| Urban Population | 3 | 2011 | 193 | 0.320 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 301 | 0.320 |
Why?
|
| Nerve Net | 1 | 2010 | 97 | 0.320 |
Why?
|
| Primary Health Care | 3 | 2017 | 690 | 0.320 |
Why?
|
| Male | 42 | 2025 | 29906 | 0.310 |
Why?
|
| Infant, Low Birth Weight | 3 | 2017 | 60 | 0.300 |
Why?
|
| Substance Abuse Detection | 2 | 2019 | 45 | 0.300 |
Why?
|
| Research Support as Topic | 2 | 2020 | 42 | 0.300 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2019 | 45 | 0.300 |
Why?
|
| Pilot Projects | 5 | 2020 | 1008 | 0.300 |
Why?
|
| Psychometrics | 6 | 2013 | 376 | 0.300 |
Why?
|
| Psychomotor Agitation | 3 | 2025 | 19 | 0.300 |
Why?
|
| Physicians | 3 | 2020 | 470 | 0.300 |
Why?
|
| Health Status | 4 | 2017 | 436 | 0.300 |
Why?
|
| Program Evaluation | 2 | 2020 | 487 | 0.290 |
Why?
|
| Mental Health Services | 2 | 2009 | 287 | 0.290 |
Why?
|
| Alcohol-Related Disorders | 2 | 2019 | 37 | 0.290 |
Why?
|
| Extraembryonic Membranes | 2 | 2025 | 5 | 0.280 |
Why?
|
| Progesterone Congeners | 2 | 2005 | 6 | 0.280 |
Why?
|
| Faculty, Medical | 2 | 2020 | 198 | 0.280 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2019 | 37 | 0.270 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1148 | 0.270 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 117 | 0.260 |
Why?
|
| Milk, Human | 1 | 2007 | 90 | 0.250 |
Why?
|
| Anger | 2 | 2016 | 23 | 0.250 |
Why?
|
| Life Style | 1 | 2008 | 311 | 0.250 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2008 | 125 | 0.240 |
Why?
|
| Abortion, Legal | 1 | 2025 | 2 | 0.240 |
Why?
|
| Women | 2 | 1998 | 44 | 0.240 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2005 | 5 | 0.240 |
Why?
|
| Drug Administration Schedule | 7 | 2006 | 298 | 0.240 |
Why?
|
| Health Behavior | 4 | 2015 | 469 | 0.230 |
Why?
|
| Abortion, Induced | 1 | 2025 | 27 | 0.230 |
Why?
|
| Affect | 2 | 2012 | 125 | 0.230 |
Why?
|
| Reproducibility of Results | 6 | 2013 | 1654 | 0.230 |
Why?
|
| Cross-Sectional Studies | 7 | 2013 | 2576 | 0.220 |
Why?
|
| Social Adjustment | 4 | 2004 | 36 | 0.220 |
Why?
|
| Child Protective Services | 1 | 2024 | 5 | 0.220 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 564 | 0.220 |
Why?
|
| Mandatory Reporting | 1 | 2024 | 16 | 0.220 |
Why?
|
| Public Health Administration | 1 | 2004 | 22 | 0.220 |
Why?
|
| Sex Factors | 9 | 2002 | 980 | 0.210 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 317 | 0.210 |
Why?
|
| Poverty | 1 | 2006 | 296 | 0.210 |
Why?
|
| Regression Analysis | 4 | 2015 | 498 | 0.210 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 72 | 0.200 |
Why?
|
| Affective Symptoms | 2 | 2002 | 15 | 0.200 |
Why?
|
| Community Health Centers | 1 | 2004 | 92 | 0.200 |
Why?
|
| Financing, Organized | 2 | 2020 | 16 | 0.200 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2022 | 12 | 0.200 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 178 | 0.190 |
Why?
|
| Brain | 1 | 2010 | 1556 | 0.190 |
Why?
|
| Restraint, Physical | 1 | 2022 | 40 | 0.190 |
Why?
|
| Personality Inventory | 4 | 2013 | 56 | 0.180 |
Why?
|
| Dysthymic Disorder | 4 | 2013 | 8 | 0.180 |
Why?
|
| Placebos | 8 | 2013 | 72 | 0.180 |
Why?
|
| Pregnancy, Unwanted | 2 | 2018 | 9 | 0.180 |
Why?
|
| Hot Flashes | 1 | 2003 | 100 | 0.180 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2021 | 33 | 0.180 |
Why?
|
| Sleep, REM | 4 | 2002 | 9 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2176 | 0.180 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 778 | 0.180 |
Why?
|
| Prescription Drug Misuse | 2 | 2019 | 21 | 0.180 |
Why?
|
| Patient Selection | 1 | 2003 | 490 | 0.170 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 26 | 0.170 |
Why?
|
| Inflammation | 2 | 2025 | 1147 | 0.170 |
Why?
|
| Behavioral Symptoms | 1 | 2020 | 14 | 0.170 |
Why?
|
| Gynecology | 1 | 2021 | 54 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 216 | 0.170 |
Why?
|
| Sex Offenses | 1 | 2021 | 47 | 0.170 |
Why?
|
| Occupational Stress | 1 | 2020 | 20 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 43 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2025 | 2081 | 0.160 |
Why?
|
| Transsexualism | 1 | 2020 | 14 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.160 |
Why?
|
| Linear Models | 2 | 2013 | 410 | 0.160 |
Why?
|
| Irritable Mood | 3 | 2015 | 16 | 0.160 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 60 | 0.160 |
Why?
|
| Self-Assessment | 3 | 2008 | 60 | 0.160 |
Why?
|
| Gender Identity | 1 | 2020 | 67 | 0.160 |
Why?
|
| Patient Participation | 1 | 2022 | 230 | 0.160 |
Why?
|
| Mindfulness | 1 | 2020 | 70 | 0.160 |
Why?
|
| Feeding and Eating Disorders | 1 | 2020 | 49 | 0.160 |
Why?
|
| Smoking Reduction | 1 | 2019 | 3 | 0.160 |
Why?
|
| Follicular Phase | 6 | 2005 | 15 | 0.150 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 23 | 0.150 |
Why?
|
| Psychotherapy | 4 | 2011 | 97 | 0.150 |
Why?
|
| Adaptation, Psychological | 2 | 2004 | 266 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 480 | 0.150 |
Why?
|
| Transgender Persons | 1 | 2020 | 69 | 0.150 |
Why?
|
| Clinical Trials as Topic | 3 | 2002 | 456 | 0.150 |
Why?
|
| Ovariectomy | 2 | 2017 | 103 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 433 | 0.150 |
Why?
|
| Education | 1 | 2019 | 68 | 0.150 |
Why?
|
| Telemedicine | 2 | 2025 | 326 | 0.150 |
Why?
|
| Program Development | 1 | 2019 | 207 | 0.150 |
Why?
|
| Prognosis | 3 | 2011 | 1748 | 0.140 |
Why?
|
| Foundations | 1 | 2018 | 9 | 0.140 |
Why?
|
| Tobacco Use Disorder | 2 | 2017 | 246 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 435 | 0.140 |
Why?
|
| Longitudinal Studies | 9 | 2005 | 1256 | 0.140 |
Why?
|
| Sexism | 1 | 2018 | 31 | 0.140 |
Why?
|
| Binge Drinking | 1 | 2018 | 36 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 83 | 0.140 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 28 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2017 | 20 | 0.140 |
Why?
|
| Qualitative Research | 4 | 2024 | 689 | 0.140 |
Why?
|
| Education, Medical | 1 | 2019 | 184 | 0.140 |
Why?
|
| Salpingectomy | 1 | 2017 | 5 | 0.140 |
Why?
|
| Harm Reduction | 1 | 2017 | 33 | 0.140 |
Why?
|
| Craving | 1 | 2017 | 36 | 0.130 |
Why?
|
| Public Health Practice | 1 | 2017 | 16 | 0.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2017 | 39 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Caregivers | 1 | 2020 | 272 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 161 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2017 | 69 | 0.130 |
Why?
|
| Complementary Therapies | 1 | 2017 | 62 | 0.130 |
Why?
|
| California | 2 | 2007 | 174 | 0.130 |
Why?
|
| Medical Records | 3 | 2007 | 137 | 0.130 |
Why?
|
| Cesarean Section | 1 | 2017 | 101 | 0.130 |
Why?
|
| Psychotropic Drugs | 3 | 1997 | 84 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2017 | 162 | 0.130 |
Why?
|
| Mobile Applications | 1 | 2017 | 136 | 0.120 |
Why?
|
| Education, Continuing | 1 | 2015 | 24 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2015 | 54 | 0.120 |
Why?
|
| Physician Assistants | 1 | 2015 | 36 | 0.120 |
Why?
|
| Cross-Over Studies | 2 | 2006 | 161 | 0.120 |
Why?
|
| Prenatal Injuries | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pregnancy, High-Risk | 2 | 2015 | 18 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.120 |
Why?
|
| Women's Health Services | 2 | 2006 | 30 | 0.120 |
Why?
|
| Inservice Training | 1 | 2015 | 86 | 0.120 |
Why?
|
| Absenteeism | 2 | 2006 | 38 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2009 | 609 | 0.110 |
Why?
|
| Birth Weight | 2 | 2015 | 85 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 296 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2016 | 1996 | 0.110 |
Why?
|
| Electroencephalography | 2 | 1998 | 149 | 0.110 |
Why?
|
| Nurses | 1 | 2015 | 108 | 0.110 |
Why?
|
| Fetal Development | 2 | 2015 | 17 | 0.110 |
Why?
|
| Sleep | 2 | 2012 | 225 | 0.110 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2013 | 2 | 0.110 |
Why?
|
| Infant | 2 | 2010 | 1648 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2005 | 863 | 0.110 |
Why?
|
| Reaction Time | 1 | 1994 | 125 | 0.110 |
Why?
|
| Psychopharmacology | 1 | 1993 | 13 | 0.100 |
Why?
|
| Rhode Island | 1 | 2013 | 100 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 937 | 0.100 |
Why?
|
| Triazoles | 3 | 1998 | 56 | 0.100 |
Why?
|
| Emotions | 2 | 2017 | 223 | 0.100 |
Why?
|
| Disease Progression | 3 | 2003 | 1172 | 0.100 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2012 | 19 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 103 | 0.100 |
Why?
|
| Agoraphobia | 4 | 1998 | 11 | 0.100 |
Why?
|
| Personality Assessment | 2 | 2007 | 28 | 0.100 |
Why?
|
| Incidence | 3 | 2011 | 1377 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2025 | 321 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2012 | 30 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 1361 | 0.090 |
Why?
|
| Menstruation | 1 | 2012 | 34 | 0.090 |
Why?
|
| Attention | 2 | 2010 | 149 | 0.090 |
Why?
|
| Remission Induction | 2 | 2003 | 148 | 0.090 |
Why?
|
| Parturition | 1 | 2012 | 55 | 0.090 |
Why?
|
| Residential Treatment | 1 | 2012 | 34 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 1993 | 158 | 0.090 |
Why?
|
| Child Development | 1 | 2012 | 85 | 0.090 |
Why?
|
| Healthy People Programs | 1 | 2011 | 11 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 978 | 0.090 |
Why?
|
| Aged | 13 | 2025 | 14443 | 0.090 |
Why?
|
| ROC Curve | 2 | 2009 | 282 | 0.090 |
Why?
|
| Imipramine | 3 | 2000 | 3 | 0.080 |
Why?
|
| Efficiency | 2 | 2003 | 41 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 1094 | 0.080 |
Why?
|
| Maternal Behavior | 1 | 2010 | 31 | 0.080 |
Why?
|
| Age of Onset | 4 | 1998 | 174 | 0.080 |
Why?
|
| Amygdala | 1 | 2010 | 83 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 215 | 0.080 |
Why?
|
| Child | 4 | 2021 | 4534 | 0.080 |
Why?
|
| Exercise | 1 | 2017 | 942 | 0.080 |
Why?
|
| Prefrontal Cortex | 1 | 2010 | 121 | 0.080 |
Why?
|
| Motor Activity | 1 | 2012 | 346 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 730 | 0.080 |
Why?
|
| Attitude to Health | 1 | 2012 | 289 | 0.080 |
Why?
|
| Cyclohexanols | 2 | 2001 | 17 | 0.080 |
Why?
|
| Chronic Disease | 6 | 2005 | 753 | 0.080 |
Why?
|
| Lithium Carbonate | 2 | 2004 | 12 | 0.080 |
Why?
|
| Single-Blind Method | 3 | 2005 | 144 | 0.080 |
Why?
|
| Remission, Spontaneous | 2 | 2000 | 14 | 0.070 |
Why?
|
| Health Care Reform | 1 | 2009 | 87 | 0.070 |
Why?
|
| Psychophysiology | 1 | 2008 | 7 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 173 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 151 | 0.070 |
Why?
|
| Personality | 1 | 2007 | 29 | 0.070 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2007 | 30 | 0.070 |
Why?
|
| Models, Psychological | 1 | 2008 | 97 | 0.070 |
Why?
|
| Case Management | 1 | 2008 | 55 | 0.070 |
Why?
|
| Data Collection | 2 | 2006 | 383 | 0.070 |
Why?
|
| Probability | 4 | 2005 | 170 | 0.070 |
Why?
|
| Models, Organizational | 1 | 2008 | 93 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2007 | 101 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 464 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 313 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1997 | 75 | 0.060 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2006 | 86 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2006 | 50 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 291 | 0.060 |
Why?
|
| Somatoform Disorders | 3 | 2009 | 13 | 0.060 |
Why?
|
| Mental Recall | 1 | 2006 | 93 | 0.060 |
Why?
|
| Serotonin | 1 | 2006 | 60 | 0.060 |
Why?
|
| Uterine Hemorrhage | 1 | 2005 | 20 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2006 | 360 | 0.060 |
Why?
|
| Patient Care Team | 2 | 2020 | 337 | 0.050 |
Why?
|
| Carbamazepine | 1 | 2004 | 11 | 0.050 |
Why?
|
| Triazines | 1 | 2004 | 16 | 0.050 |
Why?
|
| Fetal Diseases | 1 | 2004 | 21 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 46 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2004 | 26 | 0.050 |
Why?
|
| Antimanic Agents | 1 | 2004 | 31 | 0.050 |
Why?
|
| Algorithms | 1 | 2009 | 1003 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2017 | 211 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 123 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2004 | 107 | 0.050 |
Why?
|
| Receptor, Insulin | 1 | 1983 | 50 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2025 | 344 | 0.050 |
Why?
|
| Informed Consent | 1 | 2024 | 140 | 0.050 |
Why?
|
| Reference Values | 3 | 2002 | 336 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2003 | 33 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2025 | 258 | 0.050 |
Why?
|
| Piperazines | 3 | 1998 | 81 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2002 | 24 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 29 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 214 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 253 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2022 | 149 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 127 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 54 | 0.050 |
Why?
|
| Ambulatory Care | 3 | 2000 | 311 | 0.050 |
Why?
|
| Aggression | 1 | 2022 | 64 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 191 | 0.050 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2001 | 15 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2025 | 334 | 0.040 |
Why?
|
| Acute Disease | 2 | 1993 | 672 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2000 | 19 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 232 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2013 | 583 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 419 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2025 | 2157 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 104 | 0.040 |
Why?
|
| Longevity | 1 | 2021 | 113 | 0.040 |
Why?
|
| Menopause | 1 | 2003 | 258 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 303 | 0.040 |
Why?
|
| Social Stigma | 1 | 2020 | 73 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 596 | 0.040 |
Why?
|
| Insulin | 1 | 1983 | 686 | 0.040 |
Why?
|
| Alprazolam | 1 | 1999 | 4 | 0.040 |
Why?
|
| Polysomnography | 2 | 2002 | 58 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 1998 | 15 | 0.040 |
Why?
|
| Liver | 1 | 1983 | 855 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1998 | 21 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 76 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 1998 | 4 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 418 | 0.040 |
Why?
|
| Career Choice | 1 | 2019 | 132 | 0.040 |
Why?
|
| Wakefulness | 2 | 1998 | 43 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 569 | 0.040 |
Why?
|
| Family | 2 | 1997 | 238 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1998 | 47 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 83 | 0.040 |
Why?
|
| Blood Platelets | 1 | 1998 | 102 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1997 | 16 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2017 | 12 | 0.030 |
Why?
|
| Happiness | 1 | 2017 | 8 | 0.030 |
Why?
|
| Clomipramine | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sodium Lactate | 1 | 1997 | 1 | 0.030 |
Why?
|
| Buspirone | 1 | 1997 | 3 | 0.030 |
Why?
|
| Endorphins | 1 | 1997 | 12 | 0.030 |
Why?
|
| Lithium | 1 | 1997 | 21 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 86 | 0.030 |
Why?
|
| Postnatal Care | 1 | 2016 | 43 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 1996 | 106 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1997 | 141 | 0.030 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 15 | 0.030 |
Why?
|
| Dissociative Disorders | 1 | 1993 | 8 | 0.030 |
Why?
|
| Georgia | 1 | 2014 | 88 | 0.030 |
Why?
|
| Drug Users | 1 | 2014 | 30 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1994 | 97 | 0.030 |
Why?
|
| Mental Health | 1 | 2017 | 371 | 0.030 |
Why?
|
| Personality Development | 1 | 1993 | 6 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 1993 | 12 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 43 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 377 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 1994 | 262 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 761 | 0.020 |
Why?
|
| Biomarkers | 1 | 1997 | 1408 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1993 | 246 | 0.020 |
Why?
|
| Insurance Carriers | 1 | 2009 | 7 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 31 | 0.020 |
Why?
|
| Government Regulation | 1 | 2009 | 41 | 0.020 |
Why?
|
| Politics | 1 | 2009 | 35 | 0.020 |
Why?
|
| Social Behavior | 1 | 2009 | 90 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2008 | 97 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2008 | 217 | 0.020 |
Why?
|
| MEDLINE | 1 | 2006 | 13 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2006 | 16 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 77 | 0.010 |
Why?
|
| Individuality | 1 | 2005 | 22 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 240 | 0.010 |
Why?
|
| Decision Making | 1 | 2008 | 407 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 114 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2006 | 197 | 0.010 |
Why?
|
| Trypsin | 1 | 1983 | 39 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1983 | 150 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1983 | 187 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 72 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1983 | 779 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2000 | 49 | 0.010 |
Why?
|
| Premenopause | 1 | 2000 | 60 | 0.010 |
Why?
|
| Rats | 1 | 1983 | 1981 | 0.010 |
Why?
|
| Iodocyanopindolol | 1 | 1998 | 1 | 0.010 |
Why?
|
| Pindolol | 1 | 1998 | 2 | 0.010 |
Why?
|
| Receptors, Serotonin | 1 | 1998 | 16 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1998 | 24 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1998 | 52 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 719 | 0.010 |
Why?
|
| Personality Disorders | 1 | 1997 | 20 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1998 | 374 | 0.010 |
Why?
|
| Outpatients | 1 | 1997 | 142 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1998 | 1121 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 382 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 1559 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 1994 | 7 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1994 | 38 | 0.010 |
Why?
|
| Child Abuse, Sexual | 1 | 1993 | 25 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 1994 | 26 | 0.010 |
Why?
|
| Protein Binding | 1 | 1998 | 1603 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1995 | 203 | 0.010 |
Why?
|
| Animals | 1 | 1983 | 20664 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1994 | 5462 | 0.000 |
Why?
|